Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress
12 mai 2022 10h51 HE
|
Autolus Therapeutics plc
- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma- AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia-...
Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress
05 mai 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022
02 mai 2022 16h31 HE
|
Autolus Therapeutics plc
LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL
25 avr. 2022 07h01 HE
|
Autolus Therapeutics plc
LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5
25 avr. 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia
31 mars 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Participate in Conferences During April 2022
29 mars 2022 07h00 HE
|
Autolus Therapeutics plc
- Wells Fargo Annual Biotech Forum on April 12 and 13 - - 21st Annual Needham Virtual Healthcare Conference on April 14 at 8:45am ET - - 14th Kempen Life Sciences Conference on April 21 -...
Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
10 mars 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, March 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology
03 mars 2022 07h00 HE
|
Autolus Therapeutics plc
- Publication describing a novel technology that provides for very low levels of expression of one programming module relative to another programming module1 - Method for expressing stable low levels...
Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10
21 févr. 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...